Advanced Search

 

Study ID Status Title Patient Level Data
B2C108562 Completed A 2-wk study to evaluate the safety, tolerability,pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD Study Listed on ClinicalStudyDataRequest.com
B2C108784 Completed A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
B2C109575 Completed A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma Study Listed on ClinicalStudyDataRequest.com
B2C110165 Completed A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients. Study Listed on ClinicalStudyDataRequest.com
B2C111045 Completed Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD Study Listed on ClinicalStudyDataRequest.com
B2C111401 Completed A randomised, single-dose, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with and without magnesium stearate in asthmatic patients Study Listed on ClinicalStudyDataRequest.com
B2E101312 Completed A randomised, double-blind, placebo-controlled, dose ascending crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled GSK159797 delivered by dry powder inhaler in mild to moderate asthmatic subjects Study Listed on ClinicalStudyDataRequest.com
B2E106359 Completed A multi-enter, randomized, double-blind, placebo-controlled, four-way incomplete block crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20 mcg) of GSK159797 Study Listed on ClinicalStudyDataRequest.com
B2F104300 Completed A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled dry powder doses of GSK159802 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B3560634 Completed A multiple use tolerance study of six nasal strips
B3560645 Completed An evaluation of two novel Breathe Right Nasal Strip prototypes on nasal patency
B3560692 Completed A Multiple Use Tolerability study of a Breathe Right Nasal Strip Prototype
B3570674 Completed Exploratory Subjective Sleep Study of a Prototype Nasal Dilator
B3A106044 Completed A Two-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Four MR Formulations and Food Effect of GW427353 (Solabegron) in Healthy Adult Subjects
B3C109868 Completed A Randomized, Repeat Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Solabegron (GW427353) in Combination with Oxybutynin in Healthy Adult Subjects.
B3I105940 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta-3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
B3I106248 Completed An Exploratory Phase I Study in Healthy Volunteers of GI Transit following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248)
B3P104833 Completed An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women with Overactive Bladder
BACDU-001 Completed An exploratory study in healthy elderly subjects to collect urine for the development of assays to detect Streptococcus pneumoniae.
BEX104526 Completed A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH TOSITUMOMAB AND/OR IODINE I 131 TOSITUMOMAB IN STUDIES RIT-I-000, RIT-II-001, RIT-II-002, RIT-II-004, or CP-97-012
BEX104528 Completed A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036
BEX104545 Completed Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma Study Listed on ClinicalStudyDataRequest.com
BGS105049 Completed A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate (200mcg od) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety using an environmental chamber in male subjects with allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
BKB105190 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients with Idiopathic Overactive Bladder
BON103593 Completed A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.